Improvement of High-Density Lipoprotein Function in Patients With Early Rheumatoid Arthritis Treated With Methotrexate Monotherapy or Combination Therapies in a Randomized Controlled Trial

详细信息    查看全文

• 作者：Christina Charles-Schoeman ; Yuen Yin Lee ; Ani Shahbazian ; Xiaoyan Wang ; David Elashoff ; Jeffrey R. Curtis ; Iris Navarro-Millá ; n ; Shuo Yang ; Lang Chen ; Stacey S. Cofield ; Larry W. Moreland ; Harold Paulus ; James O'Dell ; Joan Bathon ; S. Louis Bridges Jr. and Srinivasa T. Reddy
• 刊名：Arthritis & Rheumatism
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：69
• 期：1
• 页码：46-57
• 全文大小：175K
• ISSN：1529-0131

文摘

Abnormal function of high-density lipoprotein (HDL) has been implicated as a potential mechanism for the increased incidence of cardiovascular (CV) disease in patients with rheumatoid arthritis (RA). This study was undertaken to evaluate changes in HDL function and HDL-associated proteins over 2 years of follow-up in patients with early RA receiving either methotrexate (MTX) monotherapy, MTX + etanercept (ETN) combination therapy, or MTX + sulfasalazine (SSZ) + hydroxychloroquine (HCQ) triple therapy in the Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial.